Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gentium, a developer and manufacturer of drugs to treat and prevent a variety of diseases and conditions, has entered into an agreement with Link Pharmaceuticals, under which Link will distribute Gentium's Defibrotide in Australia and New Zealand.
Subscribe to our email newsletter
Gentium‘s Defibrotide is an experimental drug, which is indicated as the treatment for veno-occlusive disease (VOD).
Defibrotide has been awarded orphan drug designation from the European Commission both to treat and to prevent VOD and Fast Track Designation by the US Food and Drug Administration to treat VOD.
Link CEO John Bacon said this is a potentially life-saving therapeutic and will complement Link’s portfolio of specialized and clinically essential orphan products.
"We look forward to a long collaboration with Gentium and securing the supply of Defibrotide to hospitals in Australia and New Zealand," Bacon said.